updated results from epcore nhl-2: epcoritamab plus gemox in patients with r/r dlbcl
Published 9 months ago • 254 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
1:11
epcoritamab combined with gemox in b-nhl: updated results from epcore nhl-2
-
2:42
results of phase i/ii study of epcoritamab r-dhax/c in patients with r/r dlbcl eligible for autosct
-
1:38
phase ii study of epcoritamab in r/r lbcl
-
1:06
epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
-
2:17
epcore cll-1: epcoritamab in patients with r/r cll & richter's transformation
-
1:09
early results from epcore cll-1 trial: subcutaneous epcoritamab in patients with richter’s syndrome
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
2:49
results from the phase iii echo trial of acalabrutinib plus br in mcl
-
3:17
yumizen c240 & c230 clinical chemistry analyzer (long version) - horiba
-
4:28
i-doublediff & cora technologies - horiba yumizen h550e & yumizen h500e cbc esr analyzers
-
7:50
which aml patients benefit most from venetoclax treatment?
-
2:23
results from the phase ii elm-2 trial: odronextamab for r/r follicular lymphoma
-
1:23
the importance of myeloma-specific frailty indices in trial design
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
1:14
the potential of celmods for the treatment of r/r multiple myeloma
-
1:50
novel treatment regimens under investigation for richter's transformation
-
2:51
komet-008: a phase i trial of ziftomenib combinations in kmt2a-rearranged or npm1-mutant aml
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:21
the correlation between jak2v617f molecular response and efs in patients with early pv
-
1:17
keynote-667: pembrolizumab plus copdac-28 for high-risk chl with slow early response to oepa